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Antiretroviral treatment history and past HIV-1 genotypes have been shown to be useful pre-
dictors for the success of antiretroviral therapy. However, this information may be unavail-
able or inaccurate, particularly for patients with multiple treatment lines often attending
different clinics. We trained statistical models for predicting drug exposure from current HIV-
1 genotype. These models were trained on 63,742 HIV-1 nucleotide sequences derived
from patients with known therapeutic history, and on 6,836 genotype-phenotype pairs
(GPPs). The mean performance regarding prediction of drug exposure on two test sets was
0.78 and 0.76 (ROC-AUC), respectively. The mean correlation to phenotypic resistance in
GPPs was 0.51 (PhenoSense) and 0.46 (Antivirogram). Performance on prediction of ther-
apy-success on two test sets based on genetic susceptibility scores was 0.71 and 0.63
(ROC-AUC), respectively. Compared to geno2pheno[resistance], our novel models display a
similar or superior performance. Our models are freely available on the internet via www.
geno2pheno.org. They can be used for inferring which drug compounds have previously
been used by an HIV-1-infected patient, for predicting drug resistance, and for selecting an
optimal antiretroviral therapy. Our data-driven models can be periodically retrained without
expert intervention as clinical HIV-1 databases are updated and therefore reduce our
dependency on hard-to-obtain GPPs.
1. Introduction
Prolonged chemotherapy against the human immunodeficiency virus type 1 (HIV-1) bears the
risk of selection of resistant viral strains, ultimately leading to therapy failure [1–6]. Once a
drug-resistant HIV-1 variant has been selected in a host, it can be transmitted to another host
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[6,7]. Furthermore, drug-resistant viral variants are permanently archived in the body of the
host and can promptly reemerge if drug pressure conveys them a competitive advantage to
other viral variants [8]. In order to prevent premature therapy failure, the susceptibility of an
HIV-1 variant to available antiretroviral drugs can be measured phenotypically or genotypi-
cally [4,9–12]. Due to the high cost, limited accessibility and high turnaround time of pheno-
typic resistance assays, genotypic resistance determination has become the standard of care
[4,9]. Phenotypic resistance assays afford direct, quantitative resistance assessments that
take into account resensitizing mutations [13], as well as complex mutational patterns [14].
However, certain drugs show significantly decreased in-vivo efficacy at very low in-vitro sus-
ceptibility changes which are close to the inherent variability of the phenotypic assay [15]. Fur-
thermore, viral strains with mutations that do not directly cause resistance, but are strongly
associated with the emergence of drug resistance, may be deemed susceptible by in-vitro phe-
notypic drug-resistance assays. If the respective drugs are taken by patients harboring these
strains, resistant variants will promptly emerge and compromise virologic response to therapy
[16].
Determination of genotypic resistance is performed by sequencing the viral genes coding
for the targets of antiretroviral drugs, and subsequently interpreting the resulting nucleotide
sequence [12]. A handful of tools exist for interpreting HIV-1 genotypes with respect to drug
resistance. Drug-resistance mutation tables list amino acid mutations that confer resistance to
antiretroviral drugs [14,17]. Rules-based genotypic interpretation systems score an HIV-1
genotype according to a set of rules defined by experts. The score for each drug is subsequently
discretized into two to five categories indicating increasing levels of resistance [18,19]. Data-
driven genotypic interpretation systems rely on statistical models of drug resistance for inter-
preting an HIV-1 genotype. These models are trained on sets usually containing genotype-
phenotype pairs (GPP) [20,21] generated with in vitro phenotypic assays, and can thus poten-
tially inherit their advantages and disadvantages.
HIV-1 substitutions resulting from chemotherapy are frequently divided in two groups:
major drug-resistance mutations and minor drug resistance mutations, which can also occur
as natural polymorphisms [14,17,22–26]. While there is no consensus on the definition of
these two groups of mutations, in the following, we list the defining criteria that tend to be
used. Major drug resistance mutations are frequently present in viral genotypes from patients
failing antiretroviral therapy, and appear very rarely in HIV-1 genotypes from therapy-naïve
patients. In fact, detection of such mutations in drug-naïve patients is currently interpreted as
transmission of a resistant variant from patients who have failed therapy. By themselves, major
drug-resistance mutations can either be directly responsible for drug resistance, or be informa-
tive markers for drug resistance. The implications of a mutation with respect to drug resistance
can be investigated through site-directed mutagenesis with subsequent phenotypic resistance
testing of the produced viral variant [27]. Minor drug resistance mutations tend to be poly-
morphic, and do not cause drug resistance by themselves, although they may further decrease
susceptibility to a drug in combination with major drug resistance mutations and / or compen-
sate for decreased replicative capacity resulting from selection of major mutations. In popula-
tion genetics, a polymorphism is defined as a substitution that is present in more than one
percent of the population [26,28]. The role HIV-1 polymorphisms play in chemotherapeutic
success remains controversial [23,24,29–31]. Certain polymorphisms may tend to accumulate
during chemotherapy while also being present in drug-naïve patients, albeit with a reduced
frequency [22,23]. Polymorphisms present at baseline may influence the drug susceptibility of
an HIV-1 variant [26,30–32]. Differential polymorphism distribution among HIV-1 subtypes
has been observed, however, significant implications for drug susceptibility only seem to origi-
nate from intra-subtype variability as opposed to inter-subtype variability [24,25,32]. The most
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convincing explanation for the subtype-specific distribution of natural polymorphisms seems
to be the existence of subtype-specific resistance pathways rather than subtype-specific pro-
pensity for selecting drug resistance [32].
Before drug resistance assays became available, treatment history was frequently used for
the selection of new drug regimens [33]. Nowadays, new drug regimens are sometimes selected
on the basis of treatment history when no drug resistance test is available. Indeed, statistical
models that use treatment history in place of the genotype for predicting the success of antire-
troviral therapy have been reported to be comparable to those of models that use the genotype
(and do not use therapy history) [34–37]. However, to our knowledge, these methods have not
yet found their way into clinical practice. In our experience, in today’s settings using therapy
history as a proxy for genotype incurs substantial loss of predictive power. At the same time, a
statistically significant increase in performance can be achieved by simultaneously using treat-
ment history and the genotype for predicting the success of antiretroviral therapy [34,38–43].
Drug exposure can be predicted from genotype since the virus acquires mutations as a
result of being exposed to a drug. These mutations encompass but are not limited to drug-
resistance mutations. Thus, while some of these mutations may indicate clinically relevant
drug resistance, others may also solely indicate that the virus has changed as a result of drug
exposure. As drug susceptibility is a prerequisite for the success of antiretroviral therapy, the
detection of drug exposure may pose a risk for therapeutic success (Fig 1). Reporting drug
exposure from genotype is relevant if either no established resistance-associated mutations are
detectable and / or in cases in which no treatment-history information is available. In this
work, we present statistical models that use HIV-1 genotypes to produce predictions of drug-
exposure that are correlated with both therapeutic history and drug resistance. We have devel-
oped our method in close contact with prospective users. From the resulting experience, we
expect the method to provide a significant clinical advance in bioinformatics-based therapy-
success prediction.
Note that this article is largely based on another publication from which we amply quote
[44].
2. Results
We trained models for predicting whether an HIV-1 variant had been previously exposed to a
certain drug. One or two models were trained for each of the drugs considered in this study
(Methods). Specifically, Exposure models were trained with HIV-1 sequences and information
on drug exposure. The development sets of ExposurePheno models included genotype-pheno-
type pairs (GPPs) in addition to the data included in Exposure models. Since a sufficient num-
ber of HIV-1 sequences with information on drug-exposure was not available for all drugs,
Exposure models could not be trained for all drugs. Additionally, we trained a model for dis-
criminating between HIV-1 sequences from treatment-naïve patients and HIV-1 sequences
from treatment-experienced patients. In the following, we refer to a number of datasets that
we used for training and validating our models. For the comfort of the reader, we summarize
the contents of each of these datasets in Table 1. Furthermore, we depict the relationships of
each of the datasets in Figure A in S1 File.
2.1. Dataset preparation
Prior to alignment, 48,666 nucleotide sequences with information on drug exposure were
extracted from the EuResist Integrated Database (EIDB; http://www.euresist.org) [45] and
aligned to reference sequences for the viral protease, reverse-transcriptase, and integrase. The
alignment procedure yielded 38,754 sequences for protease and reverse-transcriptase (assigned
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Fig 1. Relationship between drug exposure, drug resistance, and therapeutic success. a) Prior to drug
exposure, the virus typically does not carry drug-resistance mutations. In the absence of drug pressure, drug-
susceptible virus can replicate at high titers (dark-green viral particles). b) If drug susceptibility is given,
antiretroviral therapy frequently leads to the suppression of viral replication, which is a prerequisite for
therapeutic success. While antiretroviral therapy is administered, however, drug concentrations fluctuate over
the dosing interval and may vary within the different body compartments (orange-yellow gradient). This can
give rise to sub-inhibitory concentrations in some compartments (light-yellow area in gradient), resulting in the
selection of mutations that confer to the virus a selective advantage in the presence of the drug (light-green viral
particles). These mutations need not result in virological therapy failure, since they may not enable the virus to
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to the PRRT dataset) and 6,214 integrase sequences (assigned to the IN dataset). PRRT and IN
were further complemented with 36,774 and 5,262 sequences from therapy-naïve patients
(short: therapy-naïve sequences), respectively, from the Los Alamos National Laboratory
Sequence Database (LANLSD; http://www.hiv.lanl.gov/). The number of sequences in PRRT
was reduced to 75,239 sequences after excluding sequences with more than 10% undetermined
residues. After removal of duplicate sequences, PRRT included a total of 70,304 sequences
(approximately 93% of the initially included sequences). The number of sequences in IN was
reduced to 7,076 after excluding sequences with more than 10% undetermined residues. After
duplicate removal, 5,523 sequences (approximately 48%) were left in IN. The number of
sequences per subtype for PRRT and IN can be seen in Table 2. Sequences in PRRT and IN
were randomly assigned either to the development sets DPRRT and DIN, respectively, or to the
test sets TPRRT and TIN, respectively (Methods). Two additional test sets were created, TP and
HIVdbExposure. TP contains sequences from TPRRT and TIN which were obtained during
therapy pauses. HIVdbExposure was created from the treatment-change episode (TCE) repos-
itory in the HIV Drug Resistance Database (HIVdb) [14,46]. It contains nucleotide sequences
and lists the sets of drug compounds that had been used by the patient before the sequence was
obtained. The distribution of subtypes per sequence in HIVdbExposure can be seen in Table 2.
Table 3 shows the number of sequences in datasets DPRRT, DIN, TPRRT, TIN, TP, and HIVdbEx-
posure by drug exposure. In DPRRT, 37,557 sequences were therapy-naïve, of which 3,757
(10.0%) present transmitted drug resistance (TDR) [7]. A total of 1,917 sequences in DIN are
therapy-naïve, of which 48 (approximately 2%) present TDR. Note that the duplicate removal
procedure eliminated substantially more sequences from IN than from PRRT. TPRRT contains
2,056 therapy-naïve sequences, among which 219 (approximately 11%) present TDR, while
TIN contains 154 therapy-naïve sequences with 3 (approximately 2%) presenting TDR. We
applied the definition of the EuResist Standard Datum [40] to clinical HIV data in the EIDB
and in the HIVdb TCE repository. This yielded two datasets of TCEs with binary labels for
therapeutic success, the EuResistTCE (n = 1,650) and the HIVdbTCE (n = 1,000) datasets. Fig
2a) depicts the most frequent therapies in the EuResistTCE, while Fig 2b) does so for the TCEs
in HIVdbTCE. The baseline sequences in EuResistTCE overlap with the sequences in PRRT
partially; the baseline sequences of 619 TCEs are not included in PRRT. TCEs in EuResistTCE
whose baseline sequences were obtained during a therapy pause were assigned to the EuRe-
sistTCETP test set. EuResistTCE contains 313 first-line therapies (19.0%) among which 44
(14.1%) present TDR in their baseline sequences. No therapy in HIVdbTCE is a first-line ther-
apy. The Pheno dataset contains GPPs which were labeled susceptible or resistant using the
resistance-factor (RF) cutoffs one and ten. Pheno was randomly split into the development
and training sets DPheno and TPheno, respectively (Methods). The compositions of DPheno and
TPheno are displayed in Table 4.
2.2. Training of models for predicting drug exposure
We trained linear Support Vector classifiers (SVC) [47,48] for discriminating between
sequences from viruses with and without previous exposure to a certain drug. We trained
SVCs on two kinds of development sets, Exposure or ExposurePheno. Specifically, each
sequence in the development sets DPRRT and DIN included binary labels indicating whether
replicate at high drug concentrations. c) Recurrence of sub-inhibitory drug concentrations can ultimately select
for mutations that enable the virus to replicate even at the highest drug concentrations (red viral particles). d)
The selection of drug-resistant virus leads to virological therapy failure: the virus replicates at high titers in spite
of antiretroviral therapy.
https://doi.org/10.1371/journal.pone.0174992.g001
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Table 1. Dataset cheat sheet.
Dataset Description Input Variables Target Variables
PRRT Protease and reverse-transcriptase sequences from
the EIDB and the LANLSD, along with the drug
compounds previously used by the patient at the
time of sequencing.
Sequence of protease and
reverse transcriptase
Binary drug-exposure label for each protease
inhibitor or reverse-transcriptase inhibitor
IN Integrase sequences from the EIDB and the
LANLSD, along with the drug compounds previously
used by the patient at the time of sequencing.
Sequence of integrase Binary drug-exposure label for each integrase
inhibitor
TP Past drug compounds and sequences in PRRT and
in IN that were obtained during therapy pause.
Sequence of protease and
reverse-transcriptase or
integrase
Binary drug-exposure label for each drug
TPRRT Test set of protease and reverse-transcriptase
sequences and drug-exposure information.
Sequence of protease and
reverse transcriptase
Binary drug-exposure label for each protease
inhibitor or reverse-transcriptase inhibitor
TIN Test set of integrase sequences and drug-exposure
information.
Sequence of integrase Binary drug-exposure label for each integrase
inhibitor
DPRRT Development set of protease and reverse-
transcriptase sequences and drug-exposure
information.
Sequence of protease and
reverse transcriptase
Binary drug-exposure label for each protease
inhibitor or reverse-transcriptase inhibitor
DIN Development set of integrase sequences and drug-
exposure information.
Sequence of integrase Binary drug-exposure label for each integrase
inhibitor
EuResistTCE Test set of TCEs. Each TCE contains a protease and
reverse-transcriptase baseline sequence, the drug
compounds that were used in the therapy, and a





EuResistTCETP Test set of TCEs whose baseline sequences were
obtained during a therapy pause. Each TCE contains
a protease and reverse-transcriptase baseline
sequence, the drug compounds that were used in






HIVdbExposure Test set of protease and reverse-transcriptase
sequences and drug-exposure information.
Sequence of protease and
reverse transcriptase
Binary drug-exposure label for each protease
inhibitor or reverse-transcriptase inhibitor
HIVdbTCE Test set of TCEs. Each TCE contains a protease and
reverse-transcriptase baseline sequence, the drug
compounds that were used in the therapy, and a





Pheno Dataset of GPPs. Protease, reverse-
transcriptase or integrase
sequence
Resistance factors for different drugs
TPheno Test set of GPPs. Protease, reverse-
transcriptase or integrase
sequence
Resistance factors for different drugs or
resistance categories
DPheno Development set of genotype-phenotype pairs. Protease, reverse-
transcriptase or integrase
sequence
Resistance factors for different drugs or
resistance categories
NaïvePRRT Dataset of protease and reverse-transcriptase
sequences from treatment-naïve patients without
TDR mutations.
Sequence of protease and
reverse transcriptase
None
NaïveIN Dataset of integrase sequences from treatment-
naïve patients without TDR mutations.
Sequence of integrase None
Exposuredrug Cross-validation / development set for the compound
drug. These datasets include sequences with drug




Binary drug-exposure label for drug
ExposurenaïvePRRT Cross-validation /development set for models




Binary label indicating whether sequence was
obtained from therapy-naïve patient
(Continued )
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exposure to a particular drug had occurred or not. We used DPRRT and DIN for creating one
Exposuredrug development set for each drug and subsequently trained one SVC on each of
these development sets. We additionally created the development set ExposurenaïvePRRT in
which labels indicate whether viral sequences were derived from therapy-naïve or therapy-
experienced patients. Subsequently, we trained one SVC on ExposurenaïvePRRT. For creating
the ExposurePhenodrug development sets, we extended the data in the Exposuredrug develop-
ment sets with GPPs from DPheno. In the ExposurePhenodrug development sets, viral sequences
from GPPs labeled as susceptible to the drug in question are treated as not having being
exposed to the drug. Conversely, GPPs labeled as resistant to the drug in question are treated
as having been exposed to the drug. We trained an SVC with each ExposurePhenodrug develop-
ment set. We do not consider the binary output of the SVC classifier but rather the reported
signed distance from the decision boundary, a real number. We call this number drug-exposure
score (DES).
2.3. Assessment and comparison of performance
We constructed DES models with 10-fold cross validation on the respective development sets.
Then we used the DES reported by the resulting models and the predicted resistance factor
for geno2pheno[resistance], respectively to calculate and compare AUC performance of both
models. This was done for the test sets TPRRT, TIN, TP, HIVdbExposure, TPheno, EuResistTCE,
Table 1. (Continued)
Dataset Description Input Variables Target Variables
ExposurePhenodrug Cross-validation / development set for the compound
drug. These datasets include sequences with drug




Binary label indicating exposure or resistance to
drug. Note that this label does not distinguish
between drug exposure and drug resistance
In the table above, the names of the datasets used in this study are tabulated along with a short description of their contents. The datasets are shown in
order of appearance in Methods. Above, the term sequences refers to HIV-1 nucleotide sequences.
EIDB: EuResist Integrated Database; GPP: genotype-phenotype pair; LANLSD: Los Alamos National Laboratory Sequence Database; TCE: Therapy-
Change Episode; TDR: transmitted drug resistance.
https://doi.org/10.1371/journal.pone.0174992.t001
Table 2. Number of nucleotide sequences by subtype and dataset.
Subtype PRRT IN HIVdbExposure
B 42,634 (61%) 2,721 (49%) 1,377 (1%)
C 6,243 (9%) 1,293 (23%) 1 (< 1%)
A1 3,704 (5%) 166 (3%) 1 (< 1%)
G 3,223 (5%) 270 (5%) 0 (0%)
02_AG 3,010 (4%) 66 (1%) 1 (< 1%)
01_AE 4,275 (6%) 596 (11%) 1 (< 1%)
D 1,169 (2%) 53 (1%) 1 (< 1%)
F1 971 (1%) 69 (1%) 0 (0%)
06_cpx 312 (< 1%) 89 (2%) 0 (0%)
07_BC 651 (1%) 4 (< 1%) 0 (0%)
Other 4,112 (6%) 196 (4%) 2 (< 1%)
Total 70,304 5,523 1,381
Nucleotide sequences in the PRRT, IN, and HIVdbExposure datasets were subtyped with the Comet subtyping tool. Sequence counts for the ten most
frequent subtypes are tabulated above. For each dataset, the percentage of nucleotide sequences with a particular subtype are stated in parenthesis.
https://doi.org/10.1371/journal.pone.0174992.t002
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EuResistTCETP, and HIVdbTCE. Among the 7,275 protease and reverse-transcriptase nucleo-
tide sequences contained in TPRRT and EuResistTCE, 23 (<0.01%) were not processed by gen-
o2pheno[resistance] due to low sequence similarity. For the sake of performance comparison,
these sequences were excluded. In the following, mean performances for the tested models are
stated. In order to be able to compare the different models, these means were calculated only
with the performances of the drugs that are common to Exposure and ExposurePheno models,
as well as to geno2pheno[resistance]. p-values were calculated with a two-sided Wilcoxon signed-
rank test [49].
2.3.1. Assessment of performance for predicting drug exposure via cross validation.
We cross validated the SVC on each Exposuredrug and each ExposurePhenodrug development
set, as well as on the ExposurenaïvePRRT development set. Specifically, we performed ten repeti-
tions of a five-fold cross validation on each development set while testing a series of values
for the SVC c parameter (see Methods). One value of the c parameter was chosen for each
Table 3. Number of sequences by dataset and drug exposure.
DPRRT DPRRT Comp. DIN DIN Comp. TPRRT TPRRT Comp. TIN TIN Comp. TP TP Comp. HIVdbExposure
ABC 7,482 4,560 295 229 1,839 1,028 164 103 163 30 301
AZT 18,542 12,184 441 336 3,895 2,405 222 135 372 68 1,075
d4T 13,335 8,079 259 197 2,956 1,764 141 80 250 31 998
ddC 4,007 2,341 57 45 1,114 750 52 40 71 6 297
ddI 12,113 7,398 227 173 2,725 1,657 123 73 197 23 722
FTC 4,580 3,258 359 266 900 595 162 112 52 8 59
3TC 20,730 13,416 525 394 4,191 2,543 262 151 390 70 0
TDF 9,546 6058 479 356 1,933 1,192 211 130 119 13 219
DLV 118 56 5 2 96 58 26 18 6 1 73
EFV 9,673 6,228 301 238 2,168 1,310 168 110 194 35 400
ETR 255 169 62 51 145 94 70 48 4 3 1
NVP 8,405 5,044 232 178 1,836 1,054 123 74 179 31 508
RPV 5 4 2 1 0 0 0 0 0 0 0
APV 1,240 615 48 37 463 216 41 31 38 3 192
ATV 3,444 2,293 230 166 833 510 131 79 39 6 52
DRV 916 587 152 95 328 200 111 68 16 6 4
FPV 1,028 621 79 58 381 211 52 26 28 5 20
IDV 9,466 5,965 184 150 2,134 1,433 112 84 144 20 737
LPV 8,516 5,293 332 244 2,156 1,315 180 104 142 22 147
NFV 7,540 4,669 137 104 1,698 1,018 101 68 113 17 706
SQV 6,187 3,646 166 125 1,638 951 91 41 136 21 428
TPV 643 345 71 58 246 153 62 39 9 0 5
EVG 10 1 3 2 0 0 0 0 0 0 0
RAL 650 448 223 171 251 156 116 80 7 3 0
Naïve 37,577 37,577 1,917 1,917 2,056 2,056 154 154 3 3 0
Total 61,163 53,098 2,579 2,408 6,641 4,862 444 326 441 84 1,384
The numbers of sequences by drug exposure for the development and test datasets are tabulated above. Columns including the abbreviation Comp. in their
headers indicate the numbers of sequences from a certain dataset and with a certain drug exposure whose complete drug exposure history is known. The
complete drug exposure history for all sequences from the HIVdbExposure dataset is available.
3TC: lamivudine, ABC: abacavir, AZT: zidovudine, d4T: stavudine, ddC: zalcitabine, ddI: didanosine, FTC: emtricitabine, TDF: tenofovir, DLV: delavirdine,
EFV: efavirenz, ETR: etravirine, NVP: nevirapine, RPV: rilpivirine, APV: amprenavir, ATV: atazanavir, DRV: darunavir, FPV: fosamprenavir, IDV: indinavir,
LPV: lopinavir, NFV: nelfinavir, SQV: saquinavir, TPV: tipranavir, EVG: elvitegravir, RAL: raltegravir
https://doi.org/10.1371/journal.pone.0174992.t003
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development set. The mean drug-wise cross-validation performances (area under the receiver
operating characteristic curve; AUC) for the chosen values of c ranged between 0.67 and 0.99.
Models trained on ExposurePheno cross-validation sets had a higher mean cross-validation
performance (μ = 0.82; σ = 0.05) than those trained on Exposure cross-validation sets (μ =
0.79; σ = 0.07; p< 0.003). The p-value quantifies the difference in the AUC distributions
between Exposure and ExposurePheno models. Individual performances are depicted in Fig 3.
2.3.2. Assessment of performance for predicting drug exposure on test sets. The per-
formances of DES for predicting drug exposure on the TPRRT, TIN, TP, and HIVdbExposure
test sets are depicted in Fig 3. The performance of geno2pheno[resistance] on TPRRT, TP, and
HIVdbExposure sets can be seen in Fig 3 as well. In the following, p-values quantify the differ-
ence in the AUC distributions between Exposure models, ExposurePheno models or geno2-
pheno[resistance]. The best mean performance on the TPRRT dataset could be attained by
Exposure models (μ = 0.78; σ = 0.06), while the mean performance of geno2pheno[resistance]
was lower (μ = 0.71; σ = 0.07; p< 10−4). On the TIN dataset, DES performance for RAL was
comparable for models trained on ExposurePheno cross-validation sets (AUC = 0.71), but not
for those trained on Exposure cross-validation sets (AUC = 0.62). On the HIVdbExposure
dataset, the best mean performance with lowest standard deviation was achieved with Expo-
sure models (μ = 0.76; σ = 0.09), while geno2pheno[resistance] achieved a lower mean perfor-
mance (μ = 0.74; σ = 0.14; p = 0.43). The best mean performance on TP could be attained with
Exposure and ExposurePheno models (μ = 0.61; σ = 0.08), while geno2pheno[resistance] dis-
played a lower mean performance (μ = 0.59; σ = 0.10; p = 0.3778).
2.3.3. Assessment of performance for predicting drug resistance. Fig 4 shows the corre-
lation of DES with the logarithmized resistance factors from the TPheno dataset. DES models
trained on ExposurePheno cross-validation sets could attain substantially higher mean
Fig 2. Drug-combination counts for therapies in EuResistTCE and HIVdbTCE. The frequencies of the 20 most-frequent drug combinations in
EuResistTCE (a) and HIVdbTCE (b) datasets are displayed above. 3TC: lamivudine, ABC: abacavir, AZT: zidovudine, d4T: stavudine, ddI: didanosine,
FTC: emtricitabine, TDF: tenofovir, EFV: efavirenz, NVP: nevirapine, APV: amprenavir, ATV: atazanavir, DRV: darunavir, IDV: indinavir, LPV: lopinavir,
NFV: nelfinavir, SQV: saquinavir.
https://doi.org/10.1371/journal.pone.0174992.g002
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Table 4. Number of phenotypes by drug in the pheno datasets.
Antivirogram PhenoSense Susceptible Resistant Total
DPheno
3TC 905 1546 346 1362 2451
ABC 840 1473 531 186 2313
AZT 855 1567 801 773 2422
d4T 889 1573 1031 60 2462
ddC 821 451 371 47 1272
ddI 891 1575 654 59 2466
TDF 633 1234 850 33 1867
DLV 1016 1638 794 1091 2654
EFV 1106 1652 924 1127 2758
ETR 363 476 304 156 839
NVP 1170 1653 772 1447 2823
RPV 91 176 62 75 267
ATV 774 1134 401 978 1908
DRV 282 629 400 178 911
FPV 1088 1695 917 859 2783
IDV 1151 1734 782 1229 2885
LPV 1040 1468 665 1279 2508
NFV 1185 1780 483 1584 2965
SQV 1181 1741 985 1039 2922
TPV 742 854 584 191 1596
EVG 97 598 112 137 695
RAL 97 630 336 148 727
TPheno
3TC 115 166 37 158 281
ABC 107 166 60 25 273
AZT 107 165 92 88 272
d4T 110 168 122 6 278
ddC 105 46 38 5 151
ddI 111 168 72 7 279
TDF 87 132 87 4 219
DLV 126 169 81 125 295
EFV 141 171 105 136 312
ETR 43 52 36 15 95
NVP 146 175 82 170 321
RPV 14 21 13 10 35
ATV 85 131 42 115 216
DRV 22 79 50 20 101
FPV 110 193 88 105 303
IDV 125 194 76 142 319
LPV 113 172 76 151 285
NFV 127 199 48 189 326
SQV 129 195 105 119 324
TPV 80 106 56 22 186
EVG 17 61 9 11 78
(Continued )
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correlations (μAntivirogram = 0.46; μPhenoSense = 0.51; σAntivirogram = 0.2; σPhenoSense = 0.17)
than those trained on Exposure cross-validation sets (μAntivirogram = 0.34; μPhenoSense = 0.41;
σAntivirogram = 0.2; σPhenoSense = 0.18). We consider this sufficient correlation for the intended
use of our software. Furthermore, it should be noted that the between-test correlation of Phe-
noSense and Antivirogram is weak (r = 0.36) [11].
2.3.4. Assessment of performance for predicting therapy success. We tested the perfor-
mance of DES models and of geno2pheno[resistance] in predicting the binary therapy-success
labels of the TCEs in EuResistTCE, EuResistTCETP, and HIVdbTCE. For this purpose, we used
DES and geno2pheno[resistance], respectively, for calculating a genetic susceptibility score (GSS)
for each TCE, an additive score that rates the susceptibility of the virus to the used drugs. For
GSS calculation, the predictions of DES models and of geno2pheno[resistance] were translated
into probability scores (Methods). The GSS for a TCE is the sum of the probability scores for its
constituent drug compounds. The performances of GSS calculated with Exposure models,
ExposurePheno models, and geno2pheno[resistance], respectively, when predicting binary labels
for therapeutic success are displayed in Table 5. On the EuResistTCE dataset, the best perfor-
mance could be attained with Exposure and ExposurePheno models (AUC = 0.71), while the
performance of geno2pheno[resistance] was lower (AUC = 0.68). On therapies with baseline
sequences measured during a therapy pause (EuResistTCETP), ExposurePheno models dis-
played the best performance (AUC = 0.73), while the performance of geno2pheno[resistance] was
lower (AUC = 0.66). The best performance on HIVdbTCE is displayed by geno2pheno[resistance]
(AUC = 0.64), while the performance of drug-exposure models was lower (AUC 0.63). On
average, ExposurePheno models displayed the highest performance with lowest standard devia-
tion in predicting therapeutic success (μ = 0.69; σ = 0.05). The average performance of geno2-
pheno[resistance] when predicting therapeutic success was lower (μ = 0.66; σ = 0.02; p = 0.5).
2.4. Assessment of performance of drug-exposure models with cutoff-
based categorization
HIV-1 nucleotide sequences can be submitted to our web service for interpretation with Expo-
surePheno models (see Discussion). For the purpose of facilitating the use of DES by human
experts, we estimated cutoffs for translating DES into clinically meaningful categories. We esti-
mated two sets of cutoffs (see Methods for details). DEMax cutoffs translate DES into catego-
ries describing degrees of drug exposure (Table A in S1 File), while pheno cutoffs translate
DES into categories describing degrees of drug resistance (Table B in S1 File). For determining
and testing pheno cutoffs, we applied clinically relevant RF cutoffs to PhenoSense GPPs in
Pheno (Table C in S1 File). After discretization of DES with DEMax cutoffs, we calculated
their performance when predicting drug exposure on TPRRT, TIN, TP, and HIVdbExposure in
terms of AUC (Table D in S1 File). Furthermore, we discretized DES with pheno cutoffs and
calculated their misclassification rates when predicting drug resistance in TPheno (Table E in
Table 4. (Continued)
Antivirogram PhenoSense Susceptible Resistant Total
RAL 17 65 36 21 82
The numbers of phenotypes by drug in the DPheno and TPheno datasets are tabulated above. Phenotypes were measured with the Antivirogram™ or
PhenoSense™ assays. Resistance-factor cutoffs one and ten were used for dichotomizing phenotypes into susceptible and resistant.
3TC: lamivudine, ABC: abacavir, AZT: zidovudine, d4T: stavudine, ddC: zalcitabine, ddI: didanosine, FTC: emtricitabine, TDF: tenofovir, DLV: delavirdine,
EFV: efavirenz, ETR: etravirine, NVP: nevirapine, RPV: rilpivirine, APV: amprenavir, ATV: atazanavir, DRV: darunavir, FPV: fosamprenavir, IDV: indinavir,
LPV: lopinavir, NFV: nelfinavir, SQV: saquinavir, TPV: tipranavir, EVG: elvitegravir, RAL: raltegravir
https://doi.org/10.1371/journal.pone.0174992.t004
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S1 File). The application of cutoffs to DES can be associated with a mild loss in predictive per-
formance. When predicting drug exposure without application of cutoffs, average perfor-
mances (AUC; mean calculated with all drugs for which an ExposurePheno model is available)
on the TPRRT and TIN, TP, and HIVdbExposure datasets are 0.77 (0.06), and 0.57 (0.1), and
0.76 (0.11), respectively. After application of cutoffs, mean performance in predicting drug
exposure is 0.76 (0.06), 0.58 (0.14), and 0.76 (0.11), respectively. When predicting phenotypic
drug resistance, performance with and without application of cutoffs is difficult to compare
Fig 3. Performance of drug-exposure prediction. Performance of drug-exposure prediction was assessed with 10-fold cross validation on the
development set and four test sets. Test sets TPRRT and TIN were obtained from the EuResist database and contain protease and reverse-transcriptase
and integrase sequences, respectively. TP is a subset of TPRRT [ TIN and contains nucleotide sequences that were measured during therapy pauses.
HIVdbExposure was obtained from the HIVdb TCE repository and contains protease and reverse-transcriptase sequences. Performance on the test sets
was compared to that of geno2pheno[resistance]. Bars depicting mean performances were calculated only using drugs that are common to Exposure and
ExposurePheno models, as well as to geno2pheno[resistance]. Error bars indicate the standard deviation. 3TC: lamivudine, ABC: abacavir, AZT: zidovudine,
d4T: stavudine, ddC: zalcitabine, ddI: didanosine, FTC: emtricitabine, TDF: tenofovir, DLV: delavirdine, EFV: efavirenz, ETR: etravirine, NVP: nevirapine,
RPV: rilpivirine, APV: amprenavir, ATV: atazanavir, DRV: darunavir, FPV: fosamprenavir, IDV: indinavir, LPV: lopinavir, NFV: nelfinavir, SQV: saquinavir,
TPV: tipranavir, EVG: elvitegravir, RAL: raltegravir.
https://doi.org/10.1371/journal.pone.0174992.g003
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Fig 4. Correlation of drug-exposure scores with logarithmized resistance factors. Genotypes in TPheno were interpreted with drug-exposure models.
The correlation of the resulting drug-exposure scores with the corresponding logarithmized resistance factors is displayed above. Note that drug-
resistance assays (either Antivirogram™ or PhenoSense™) are denoted by the colors of the bars, while the drug-exposure model types (Exposure or
ExposurePheno) are denoted by the shading of the bars. Bars depicting the mean performances were calculated with the drugs for which Exposure and
ExposurePheno models are available. Error bars indicate the standard deviation. 3TC: lamivudine, ABC: abacavir, AZT: zidovudine, d4T: stavudine, ddC:
zalcitabine, ddI: didanosine, FTC: emtricitabine, TDF: tenofovir, DLV: delavirdine, EFV: efavirenz, ETR: etravirine, NVP: nevirapine, RPV: rilpivirine, APV:
amprenavir, ATV: atazanavir, DRV: darunavir, FPV: fosamprenavir, IDV: indinavir, LPV: lopinavir, NFV: nelfinavir, SQV: saquinavir, TPV: tipranavir, EVG:
elvitegravir, RAL: raltegravir.
https://doi.org/10.1371/journal.pone.0174992.g004
Table 5. Performance of prediction of therapy-success for therapies in EuResistTCE, EuResistTCETP, and HIVdbTCE.
Exposure ExposurePheno geno2pheno[resistance]
EuResistTCE 0.71 0.71 0.68
EuResistTCETP 0.72 0.73 0.66
HIVdbTCE 0.62 0.63 0.64
Therapy success was predicted for therapies in the EuResistTCE, EuResistTCETP, and HIVdbTCE test using three different genetic susceptibility scores
(GSS) for each therapy. The first GSS was obtained with Exposure models, the second GSS with ExposurePheno models and the third GSS with
geno2pheno[resistance]. Above, the performances of the three different GSS are tabulated for each dataset. Performances were quantified with the area
under the receiver operating characteristic curve.
https://doi.org/10.1371/journal.pone.0174992.t005
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since different performance measures are required for each case. Specifically, without applica-
tion of cutoffs, performance was measured with the Pearson correlation coefficient, while with
application of cutoffs, performance was measured with the misclassification rate. With applica-
tion of cutoffs, the mean misclassification rate is 0.27 (0.1) for all GPPs, 0.11 (0.06) for suscepti-
ble-labeled GPPs, 0.1 (0.06) for intermediate-labeled GPPs, and 0.05 (0.03) for resistant-labeled
GPPs.
3. Discussion
DES models constitute data-driven interpretation systems for HIV-1 protease, reverse-tran-
scriptase, and integrase sequences. Two versions of DES models were trained and tested.
Specifically, one version of the models is solely trained on genotypes and drug exposure infor-
mation (Exposure models), while the other version additionally includes GPPs (Exposure-
Pheno models). When compared to ExposurePheno models, Exposure models show a high
performance when predicting drug exposure, but their correlation with RFs and their perfor-
mance when predicting antiretroviral therapy success are lower. We chose to include GPPs in
the training sets of ExposurePheno models for the following reasons. Both drug exposure and
drug resistance are predictive of success of antiretroviral therapy [34,38–40]. The major factor
leading to viral drug resistance is exposure to antiretroviral drugs. Specifically, drug resistance
arises through the selection of HIV-1 strains with mutations that confer a replicative advantage
in the presence of the drug. Thus, drug exposure indirectly causes drug resistance and there-
fore, both drug exposure and drug resistance are correlated with certain mutations in the
genome of HIV-1. Nevertheless, drug exposure and drug resistance are not redundant, but can
complement each other. For this reason, simultaneous interpretation of HIV-1 genotypes with
respect to drug exposure and to drug resistance is useful for the prediction of the success of
antiretroviral therapy. ExposurePheno models consider drug exposure and drug resistance
jointly. For the purpose of including GPPs in the training set of classification models, RFs
required categorization. Thus, we replaced the RFs in the GPPs with the labels susceptible and
resistant. For the purpose of labeling, the RF cutoffs one and ten were applied to all GPPs,
regardless of the drug-resistance test (Antivirogram or PhenoSense) and of the tested drug.
GPPs with RFs between one and ten were not used for training the models. When clinically
relevant categorization of GPPs is intended, different cutoffs for each drug and drug resistance
test must be used [15]. However, rather than producing clinically relevant labels for training,
we aimed at discriminating fully susceptible GPPs from those that have developed resistance
to an extent well beyond the variability arising from the drug resistance test itself, for the fol-
lowing reasons. First, drug resistance is a continuum, and the creation of training instances
with a clear separation in this continuum is adequate for the training of binary classification
models. Second, clinically relevant cutoffs are selected under the (implicit) consideration of
the pharmacokinetic properties of a drug. For example, the use of ritonavir as a booster for
protease inhibitors (PIs) leads to an increased and sustained concentration of PIs in the body
[50]. For this reason, clinically relevant cutoffs for boosted PIs are shifted upwards with respect
to their unboosted counterparts [15]. However, we aim at discriminating viral sequences that
display mutations as a consequence of drug exposure (or as the cause of resistance), without
regard for drug concentrations in the blood of patient. The cutoffs one and ten are adequate
for combining GPPs produced with the Antivirogram and PhenoSense assays; if other assays
are used, other cutoffs might need to be selected. One advantage of ExposurePheno models
over Exposure models is their higher performance. Another advantage is that they can make
use of an additional data source, the GPPs. The use of GPPs allowed for the training of models
for two additional drugs (EVG and RPV).
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The interpretations provided by DES models can be used to addresses three questions: (1)
Was an HIV-1 variant exposed to a certain drug? (2) Is an HIV-1 variant resistant to a certain
drug? and (3) How does the effect of a drug combination therapy decompose into effects of its
constituent drugs? In the following, we propose how DES models can be used for addressing
the three questions mentioned above.
Ad question (1): When the prediction of drug exposure is required, we propose two ways in
which DES can be used. For quantification and comparison of the degree of drug exposure
between at least two groups of patients, we do not recommend translating DES into categories
(by using cutoffs), since this leads to loss of precision. Instead, DES should be directly used for
detecting differences between groups. Note that comparison of DES for different drugs requires
normalization, e.g. via the calculation of z-scores (this is provided by our web service). If the
prediction of the drug exposures of individual patients is required, cutoffs can be used in order
to translate DES into clinically meaningful categories (this is also provided by our web service).
Ad question (2): When predicting drug resistance with DES, one should bear in mind that
the correlation of DES with log RFs is weak to strong, depending on the drug in question (Fig
4). Correlation with drug resistance to the nucleotide and nucleoside reverse-transcriptase
inhibitors (NRTIs) AZT, d4T, ddC, ddI, and TDF is lower than with resistance to other drugs.
We interpret this to be the result of the high similarity of the resistance profiles among these
NRTIs [17]. Mutations conferring resistance to one of these NRTIs confer resistance to the
other NRTIs (cross-resistance) and are thus less discriminative of exposure and resistance to
any specific drug among the NRTIs we mention above. Nonetheless, the correlation is suffi-
cient for predicting the susceptible-intermediate-resistant (SIR) label of GPPs discretized with
clinically relevant cutoffs (Table E in S1 File). While a mean misclassification rate of 0.27 (0.1)
seems high, most of errors arise from misclassifying intermediate-labeled GPPs (μ = 0.1; σ =
0.06), for which the clinical relevance is uncertain [12], and from misclassification of suscepti-
ble-labeled GPPs that are predicted to be intermediate or resistant (μ = 0.1; σ = 0.06). For the
drugs AZT, d4T, ddI, and TDF, misclassification of susceptible- and intermediate-labeled GPPs
as resistant is especially high, which we also attribute to the high similarity of their resistance
profiles. Misclassifying susceptible-labeled GPPs as intermediate or resistant can be clinically
adequate, for the following reason. Phenotypic resistance measurements do not account for
mutations that do not cause drug resistance at the time of resistance testing, but are indicative
that drug resistance can be easily developed in the future [16]. Therefore, when such resistance
mutations are present in the viral baseline genotype of a patient, and even if phenotypic resis-
tance measurements indicate full drug susceptibility, classification of the genotype as non-sus-
ceptible will prevent selecting a combination of drug compounds that could quickly fail due to
the emergence of drug resistant viral variants. Nonetheless, misclassifying susceptible-labeled
GPPs as intermediate or resistant could also lead to rejection of a drug for treating a patient
although the drug could have been a good choice. When the prediction of the results of pheno-
typic resistance tests is required, we recommend the use of interpretation systems that have
been specifically designed and validated for this purpose, e.g. geno2pheno[resistance]. DES pre-
dictions are especially useful in two situations: first, when (imminent) drug resistance is not
detected by other methods because the process of selection of drug-resistant variants has led to
the selection of certain mutations that have not (yet) resulted in clinically relevant drug-resis-
tance (Fig 3; ExposurePheno models have a higher performance in predicting drug exposure
than geno2pheno[resistance]). Second, when drug-resistant HIV-1 variants are in the process of
reverting to the wild type after the removal of drug pressure (Fig 3 and Table 5; ExposurePheno
models have a higher performance in predicting drug exposure and therapeutic success than
geno2pheno[resistance] when genotypes were obtained during therapy pauses). Decision support
for the choice of the use of the tool will be given in our follow-up paper.
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Ad question (3): DES are predictive of therapeutic success (Table 5). In order to facilitate
the use of DES for deciding which drug could be useful components of combination antiretro-
viral therapy, as well as for interpretation of DES by human experts, our online web service
offers the following features. (i) Calculation of DES. (ii) Calculation of z-scores, which normal-
ize DES with respect to their distribution in therapy patients. These z-scores can be useful
when DES for different drugs need to be compared or merged for the analysis of clinical
data. (iii) Translation of DES into categories related to drug exposure and drug resistance via
cutoffs. HIV-1 can mutate as a result of exposure to antiretroviral drugs, which does not neces-
sarily entail clinically relevant drug resistance. Drug-exposure categories help the user to deter-
mine whether a viral variant has changed as a result of drug exposure. If a viral variant is not
rated unexposed for a certain drug, drug resistance to that drug should be at least suspected.
Drug-resistance categories indicate whether viral mutations are not only indicative of exposure
to a particular drug, but also indicative of clinically relevant drug resistance. If a viral variant is
not rated susceptible, drug resistance is highly likely. Drug-exposure and drug-resistance cate-
gories are useful when selecting the drug components of antiretroviral therapy. However, pre-
dictions are provided for each drug individually (as in most drug-resistance interpretation
tools). Thus, the selection of an adequate drug combination under consideration of DES is still
left to the expert. In a follow-up paper we will report on a DES-based model that does not
require expert selection of drug combinations. Specifically, we are currently testing DES as
input features for a model for predicting the success of combinations of antiretroviral drugs.
This model will exploit DES for selecting the compounds of antiretroviral therapy. (iv) Presen-
tation of the basis of the predictions by displaying the residues with the largest influence on the
prediction.
In summary, in this study, we present a novel approach for training a data-driven interpre-
tation system for drug exposure and drug resistance. We show that models trained on HIV-1
sequences from patients with known drug history can be used for predicting drug exposure,
drug resistance, and therapeutic success, even if no GPPs are used. The inclusion of GPPs in
the training sets of the models boosted the performance of the models when predicting in-vitro
phenotypic drug resistance measurements and therapeutic success, but not when predicting
drug exposure. Compared to geno2pheno[resistance], the method could attain higher mean per-
formances when predicting drug exposure and therapeutic success. The difference in perfor-
mance was only statistically significant at the 5% level when predicting drug exposure on
TPRRT. Note that many of the drugs in HIVdbTCE are not used any more due to their toxicity
profiles or their comparatively low potency. A large advantage of DES models is that they are
trained on clinical HIV data and freely available GPPs. In conjunction with a frequently
updated database with HIV-1 data from routine clinical practice, such as the EIDB, DES mod-
els can be automatically updated on a regular basis. Thus, these models allow us to reduce our
dependency on hard-to-obtain GPPs for offering a publicly available data-driven genotypic
drug-exposure and drug-resistance interpretation system that is kept up to date. While regu-
larly updatable interpretation systems are clearly the appropriate method for accounting for
the growing richness of clinical data, innovative procedures may have to be put in place for
adequate certification of such systems. DES models for protease and reverse transcriptase
inhibitors have been integrated into the geno2pheno[resistance] server http://www.geno2pheno.
org. Support for integrase inhibitors will follow. After a sequence has been submitted for pre-
diction, the tab labeled Drug Exposure must be selected in order to view DES predictions. Note
that in the input tab, sample nucleotide sequences can be loaded by selecting the appropriate
action. On the website, mutations with the highest influence on the prediction are displayed.
These are ordered by the magnitude of their influence. Mutations colored in red increase DES,
while those colored in green decrease it.
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4. Materials and methods
4.1. Ethics statement
All data considered in this study had been previously de-identified. For this reason, consent
was neither required nor given by human subjects.
4.2. Drugs considered in this study
In this study, the following antiretroviral drugs are considered: lamivudine (3TC), abacavir
(ABC), zidovudine (AZT), stavudine (d4T), zalcitabine (ddC), didanosine (ddI), emtricitabine
(FTC), tenofovir (TDF), delavirdine (DLV), efavirenz (EFV), etravirine (ETR), nevirapine
(NVP), rilpivirine (RPV), amprenavir (APV), atazanavir (ATV), darunavir (DRV), fosampre-
navir (FPV), indinavir (IDV), lopinavir (LPV), nelfinavir (NFV), saquinavir (SQV), tipranavir
(TPV), raltegravir (RAL) and elvitegravir (EVG). Other antiretroviral drugs were excluded due
to insufficient data.
4.3. Dataset construction
In the following, we describe a number of datasets that we used for training and validating our
models. For the comfort of the reader, we summarize the contents of each of these datasets in
Table 1. Furthermore, we depict the relationships of each of the datasets in Figure A in S1 File.
4.3.1. Datasets of genotypes and therapeutic history. The PRRT and IN datasets contain
HIV-1 nucleotide sequences and information on the antiretroviral compounds that were used
before each sequence was obtained. When constructing these datasets, we disregarded episodes
of treatment with a drug that lasted less than 30 days. The PRRT dataset was constructed by
pooling 70,304 HIV-1 protease (PR) and reverse-transcriptase (RT) nucleotide sequences from
two sources: 37,799 sequences from the EuResist Integrated Database (EIDB; http://www.
euresist.org, downloaded April 11th, 2014) [45], 9,627 of which were derived from drug-naïve
patients (short: drug-naïve sequences), and 32,506 drug-naïve sequences from the Los Alamos
National Laboratory Sequence Database (LANLSD; http://www.hiv.lanl.gov/; downloaded on
March 31st, 2015). Among the sequences in the PRRT dataset that were derived from therapy-
experienced patients (short: drug-exposed sequences), 18,328 sequences were derived from
patients whose complete drug history was available at the time of sequencing. The IN dataset
includes a total of 5,523 integrase (IN) nucleotide sequences with the following characteristics:
3,382 sequences were extracted from the EuResist database, 1,240 of which are drug-naïve, 397
have been exposed to an integrase inhibitor (INI) and possibly other drugs, and 1,745 have
been exposed only to drugs whose target is different from integrase. The complete drug history
was available for 1,432 of the drug-exposed integrase sequences. Additionally, 3,782 drug-
naïve integrase sequences from the LANLSD (downloaded on March 31st, 2015) were added to
the IN dataset. Inclusion criteria for the sequences were as follows. (1) Alignment with the
MutExt software (http://www.schuelter-gm.de/mutext.html) must not have produced an error
due to low sequence similarity to the reference sequence (2) at most 10% of the residues of the
considered protein regions could not be determined by the sequencing procedure (considered
protein regions are listed in Section Subtype Determination, Sequence Alignment and Encod-
ing), (3) the amino-acid sequence resulting from nucleotide translation must be unique within
the dataset, unless drug exposure differed between duplicates. The order of appearance of the
sequences in the dataset determined which duplicate sequence was excluded, with sequences
appearing first preempting inclusion of sequences appearing later. Older reverse-transcriptase
sequences not covering amino-acid positions 221–230 were excluded as well.
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PRRT and IN were split into development and test sets, as follows. For the purpose of rigor-
ous validation, HIV-1 nucleotide sequences derived from the same patient were not allowed to
be simultaneously present in the development and test sets. In the following, dataset nomen-
clature consists of an abbreviation describing a characteristic of the dataset and optionally
PRRT or IN in subscript. The letters in subscript indicate whether the dataset is a subset of the
PRRT or of the IN dataset. All HIV-1 nucleotide sequences in PRRT and IN that were obtained
during a therapy pause were assigned to TP (n = 441). This dataset is only used for testing pur-
poses, since we deem therapy-pause sequences valuable for testing and an insignificant minor-
ity in the much larger training set. In order to make sure that the test sets are patient-wise
disjoint with respect to the development set, a set of test patients P was created iteratively. Ini-
tially, P included all patients with sequences in TP. Further patients from PRRT and IN were
subsequently added to P by random selection until the number of available sequences for the
patients in P was approximately 10% of the number of sequences in PRRT and IN. The test
sets TPRRT and TIN contain the protease and reverse-transcriptase sequences available for the
patients in P, respectively. The development sets DPRRT and DIN contain the sequences in
PRRT and IN, respectively, that are not included in TPRRT, and TIN.
4.3.2. EuResistTCE dataset and standard datum definition. In order to test the perfor-
mance of our models in predicting therapeutic success, we created the EuResistTCE test set, as
follows. We extracted a total of 9,201 therapy-change episodes (TCEs) from the EIDB [45].
These TCEs were constructed according to the definition of the EuResist Standard Datum
[40]. In contrast to the EuResist Standard Datum, however, viral-load (VL) measurements
were constrained to those not reaching a lower limit of quantification greater or equal than 50
HIV-1 RNA copies per milliliter of blood plasma. In summary, each TCE includes a protease
and reverse transcriptase baseline sequence, the compounds that were prescribed to the
patient, a baseline and a follow-up viral load (VL), and a binary label indicating whether the
therapy was successful or not. The follow-up VL must have been measured within 4–12 weeks
after therapy start, preferring the VL closest to week 8 after therapy start. Therapy success at
follow up is defined as an at least 100-fold reduction in the VL or a VL of less than 400 HIV-1
RNA copies per ml of blood plasma. This definition of therapy success was used for producing
binary labels for the TCEs. To allow performance comparison, only therapies including the fol-
lowing antiretroviral drugs were considered: 3TC, ABC, AZT, d4T, ddI, FTC, TDF, EFV, ETR,
NVP, APV, ATV, DRV, FPV, IDV, LPV, NFV, SQV, TPV and ritonavir as a boosting agent
(/r). Therapies including unboosted protease inhibitors (except for NFV, since the drug cannot
be boosted) were excluded due to their comparatively inferior potency.
The baseline sequences of the EuResist TCEs partially overlap with the sequences in the
datasets described above. A minority of baseline sequences were not included in any of the
datasets described above because we could not ascertain whether drug exposure had occurred
or the patient was therapy-naïve at the time of sequencing. We created a set of test TCEs, EuR-
esistTCE, with a fraction of the initially extracted EuResist TCEs. Specifically, EuResistTCE
only contained TCEs with baseline sequences that had not been derived from a patient with an
HIV-1 nucleotide sequence in DPRRT or in DIN. A subset of the TCEs in EuResistTCE includes
baseline sequences which were obtained during a therapy pause. We refer to these TCEs as
EuResistTCETP.
4.3.3. HIVdbExposure and HIVdbTCE datasets. For testing the performance of our
models in predicting drug exposure and therapeutic success, we created the HIVdbExposure
and the HIVdbTCE test sets, respectively. The TCE repository in the HIV Drug Resistance
Database was downloaded in its entirety on November 21st, 2013 [14,46]. The TCE repository
contains 58 TCEs from the EuResist database, which were discarded. A total of 1,384
sequences with drug-exposure information could be extracted from the repository. We
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assigned these sequences to the HIVdbExposure test set. For creating the HIVdbTCE test set,
the EuResist Standard Datum definition was applied to therapies in HIVdbTCE whose drug
compounds are investigated in this study (with the exception of ddC and raltegravir (RAL) for
the sake of performance comparison).
4.3.4. Datasets of genotype-phenotype pairs. A total of 7,597 GPPs were downloaded
from the HIV Drug Resistance Database [14] on April 15th, 2015 (Pheno dataset). The pheno-
typic drug-resistance assays used for producing the phenotypes were constrained to Antiviro-
gram1 [51] and PhenoSense1[52]. The genotypes are provided in the form of substitutions
with respect to the reference sequence consensus B [14]. 3,323 GPP quantify protease-inhibitor
(PI) resistance, 3,477 reverse-transcriptase-inhibitor (RTI) resistance, and 797 INI resistance.
The TPheno test set was created from the Pheno dataset by randomly sampling approximately
10% of the GPP. The rest of the GPPs in Pheno were assigned to the DPheno development set.
For training our models with the GPPs, we categorized the resistance factors (RFs) in DPheno
as susceptible or resistant. Specifically, GPPs with RFs lower or equal to one were categorized as
susceptible, while GPPs with RFs greater or equal to ten were categorized as resistant. GPPs
with RFs between one and ten were not used for training our models.
4.3.5. NaïvePRRT and NaïveIN datasets. Transmitted drug resistance (TDR) in PR- and
RT-naïve sequences was defined as the presence of at least one mutation in the list of drug
resistance mutations for surveillance of transmitted HIV-1 drug resistance (DRMT) [7]. Since
the list of DRMT only contains PR and RT mutations, TDR in IN sequences was defined as the
presence of an INI drug-resistance mutation in the 2013 IAS list [17]. Following the methodol-
ogy used for establishing the list of DRMT, INI drug-resistance mutations with a prevalence
greater than 0.5% among sequences from the LANLSD in IN were not regarded as indicative
of TDR [28]. The NaïvePRRT and NaïveIN were created by randomly sampling 2,500 LANLSD
sequences without TDR from the PRRT and IN datasets, respectively. These sequences are not
included in TPRRT, TIN, DPRRT or DIN. NaïvePRRT and NaïveIN are used by our web service for
z-score calculation.
4.4. Subtype determination, sequence alignment and encoding
The subtype distribution in the PRRT and IN datasets was determined with the COMET sub-
typing tool [53]. Nucleotide sequences in PRRT and IN were aligned against HXB2 and trans-
lated, using MutExt (http://www.schuelter-gm.de). The resulting amino-acid sequences, along
with amino-acid sequences in the Pheno dataset, were represented vectorially with a binary
encoding. The vectorial representation considers substitutions, deletions and the presence of
insertions within the following HXB2 amino-acid positions: protease 3–99, reverse transcrip-
tase 40–230, and integrase 30–260. The presence of deletions and insertions was encoded for
each amino-acid position, while the amino acids of which a specific insertion consists were not
encoded.
4.5. Creation of exposure and ExposurePheno development sets
DPRRT and DIN were used for constructing the development sets Exposuredrug for drug 2
{ABC, AZT, d4T, ddC, ddI, 3TC/FTC, TDF, EFV, ETR, NVP, RPV, ATV, DRV, APV/FPV,
IDV, LPV, NFV, SQV, TPV, RAL, EVG} which contain an equal number of sequences exposed
and not exposed to a certain drug, along with binary labels indicating exposure to the drug.
Sequences not exposed to the drug were randomly selected from DPRRT or DIN, as they were in
excess; these sequences were required to have been derived from patients whose complete
drug exposure history is recorded. Where possible, half of the sequences not exposed to the
drug were drug-naïve, and half of them were exposed to some other drug. A development set
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ExposurenaïvePRRT containing an equal number of drug-naïve and drug-experienced PRRT
sequences was constructed as well. An ExposurenaïveIN development set was not created due to
the fact that only a sufficient number of RAL-exposed integrase sequences was available.
The ExposurePhenodrug development sets were created from the Exposuredrug sets with
additional supplementation of some GPPs from the DPheno dataset. Specifically, genotypes
with corresponding RFs classified as resistant were treated as drug-exposed sequences while
those with corresponding RFs classified as susceptible were treated as sequences not exposed
to the drug in question. Genotypes with corresponding RFs between the two cutoffs were
not used for training (see Phenotypic Resistance Cutoffs). This procedure incremented the
number of available drug-exposed sequences and allowed for the creation of the development
sets ExposurePhenoRPV and ExposurePhenoEVG, as the number of available drug-exposed
sequences for RPV and EVG was very low. Development sets for dolutegravir could not be cre-
ated, as neither a sufficient number of resistant phenotypes nor a sufficient number of drug-
exposed sequences were available.
4.6. Training and selection of models for predicting drug exposure
For performing five repetitions of a 10-fold cross validation, each Exposuredrug and each Expo-
surePhenodrug set was randomly partitioned five times into ten folds. Each fold contained an
equal proportion of sequences with and without exposure to the drug in question. The parti-
tions were used to cross validate linear support-vector classifiers (SVCs) [47,48] discriminating
between sequences with and without exposure to a certain drug. The vectorial representation
used to train each drug-specific model was constrained to the vector elements describing the
drug’s target protein (protease, reverse transcriptase or integrase). Each cross validation was
performed with a certain value for the regularization parameter c for the SVM, specifically,
c 2 {2−8, 2−7, . . ., 22}. Performance was measured in terms of the area under the receiving-
operator-characteristic curve (AUC) [54,55]. The signed distance to the classification hyper-
plane (also called decision value) was used as a score for predicting drug exposure. Thus, we
call such decision values drug-exposure scores (DES). For each cross-validation set and vecto-
rial representation, the model with the lowest value of c whose average performance was not
significantly lower than the best average performance was selected (Benjamini-Hochberg-cor-
rected Wilcoxon signed-rank test [49] with a significance threshold of 0.05). Finally, each
cross-validation set and vectorial representation was used without partitioning to train a final
SVC with the selected value of c. We refer to these SVCs as the final DES models.
4.7. Assessment and comparison of performance
The performance of the drug-exposure models was compared to that of geno2pheno[resistance]
3.3 (http://www.geno2pheno.org) [20]. The output of geno2pheno[resistance] includes a predic-
tion of the resistance-factor (RF). Since geno2pheno[resistance] uses its own alignment program,
performance comparison was constrained to the set of sequences which could be aligned with-
out errors by geno2pheno[resistance]. Furthermore, the drug ddC was also excluded from perfor-
mance comparison, as it is not supported by geno2pheno[resistance] any more.
Assessment of performance. Sequences in TPRRT, TIN, TP, EuResistTCE, EuResistTCETP,
HIVdbTCE, HIVdbExposure, and TPheno were interpreted with the final drug-exposure mod-
els and geno2pheno[resistance]. Performance was assessed in three respects. First, the perfor-
mance of DES and of geno2pheno[resistance] when predicting drug exposure was assessed using
TPRRT, TIN, TP, and HIVdbExposure. These datasets contain HIV-1 sequences and a binary
matrix indicating the previous exposure of these sequences to each individual drug compound.
The area under the receiver operating characteristic curve (AUC) was used as a performance
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measure. Second, the performance of DES when predicting drug resistance was quantified
with the correlation between DES for the genotypes in TPheno and the corresponding log RFs.
Unfortunately, performance in predicting drug resistance could not be compared to that
of geno2pheno[resistance], since the genotypes in TPheno were only available as amino-acid
sequences and geno2pheno[resistance] requires nucleotide sequences as an input. Third, the per-
formance of DES and of geno2pheno[resistance] when predicting therapy success was assessed
with EuResistTCE, EuResistTCETP, and HIVdbTCE. For this purpose, DES and RF predic-
tions were converted to probability scores. Specifically, DES, which are SVM decision values,
were converted to probability scores as described by Platt [56]. Predicted RFs were converted
to probability scores by fitting a two-component Gaussian-mixture model. In the Gaussian
mixture model, one Gaussian is fitted to RFs that belong to the susceptible population, while
the other Gaussian is fitted to RFs that belong to the resistant population. Subsequently, a sig-
moid function is used for estimating the probability of resistance [20]. We define the probabil-
ity of susceptibility as one minus the probability of resistance. Probability scores were used for
calculating a genetic susceptibility score (GSS) for each therapy. A GSS consisted of the sum of
the individual probability scores for each drug in the regimen. For each therapy, three GSS
were calculated. The first two GSS were calculated using the probability scores derived with
DES from Exposure and ExposurePheno models, respectively, while the third GSS was calcu-
lated with the probability scores derived with geno2pheno[resistance]. Performance in predicting
therapeutic success was quantified with the AUC. Significance values in the Results section
were calculated with a two-sided Wilcoxon signed-rank test [49].
4.8. Determination of parameters for our web service
Our drug-exposure models are freely available online (http://www.geno2pheno.org; see Dis-
cussion). For the purpose of facilitating the use of DES by human experts, we calculated
two sets of parameters. The first set of parameters is used for calculating z-scores of DES. It
includes a mean and a standard-deviation value for each drug, calculated with the nucleotide
sequences in NaïvePRRT and NaïveIN. The second set of parameters includes cutoffs which
translate DES into clinically meaningful categories related to drug exposure and drug resis-
tance. For the purpose of displaying the sequence features with the largest influence on the pre-
dictions of DES models, we translated the Support Vectors and corresponding Support-Vector
coefficients of each SVC into a linear function. In the following, we detail on the procedures
we used for determining the z-score parameters, the cutoffs, and for extracting the weights for
the input features.
4.8.1. Calculation of z-scores from drug-exposure scores. We interpreted each sequence
in NaïvePRRT with each DES model for predicting exposure to protease inhibitors (PIs) and
reverse-transcriptase inhibitors (RTIs). Likewise, we interpreted each sequence in NaïveIN
with each DES model for predicting exposure to INIs. For each drug, we calculated the mean
and standard deviation of the resulting DES. Our web service calculates the z-score for a





where zdrug(s) is the z-score for sequence s and compound drug, δdrug(s) is the DES for
sequence s and compound drug, μdrug is the mean DES value calculated with the NaïvePRRT or
NaïveIN datasets, and σdrug is the corresponding standard deviation.
4.8.2. Estimation of cutoffs of drug-exposure scores. Two sets of cutoffs were deter-
mined for each final DES model. The following goals are addressed by each set of cutoffs: (1)
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prediction of drug exposure and (2) prediction of drug resistance. Each set of cutoffs includes
a lower and an upper cutoff for the corresponding DES models. The description of the meth-
ods used for determination of these cutoffs follows.
4.8.3. Cutoffs maximizing the performance of the prediction of drug exposure (DEMax
cutoffs). ExposurePhenodrug cross-validation sets were interpreted with the corresponding
final DES models that were trained on them (this is also called calculation of reinsertion pre-
dictions). For each cross-validation set, an upper and a lower cutoff were estimated such that
the AUC of the drug-exposure prediction is maximized. We call these cutoffs the DEMax cut-
offs, and they allow for the discretization of a DES for a drug into the categories unexposed
(U), possible exposure (PE) and probably exposed (E). A detailed description of the procedure
with which DEMax cutoffs were determined follows.
Function (1) was defined for discretization of a value δs 2 R associated to a sequence s by
using the lower and upper cutoffs cL, cU 2 R.
discretizeðcL; cU; dsÞ ¼
1; if ds < cL
2; if cL  ds  cU





Let Δdrug 2 Rn be a vector of DES predicting the drug exposure of each of n sequences s to
drug, and let Edrug 2 {0,1}n be the corresponding vector of class labels, indicating whether each
sequence s was exposed to the drug or not. Application of cutoffs cL, cU and Function (2) to a
vector of DES Δdrug results in the discrete DES vector discretize(cL, cU, Δdrug). For each boot-
strap replicate, an upper and a lower cutoff cL and cU were determined as
argmax
cL; cU
AUCðdiscretizeðcL; cU; DdrugÞ; EdrugÞ ; ð3Þ
where AUC(discretize(cL, cU, Δdrug), Edrug) is the AUC quantifying the performance of discre-
tize(cL, cU, Δdrug) in predicting exposure to drug for each sequence with a DES in Δdrug. AUC
maximization was performed via grid search over cL and cU.
ExposurePhenodrug cross-validation sets were interpreted with the corresponding final
models that were trained on them. Two thousand bootstrap replicates of the DES of each
cross-validation set were created. For each bootstrap replicate and the corresponding class
labels, an upper and a lower cutoff were determined by AUC maximization Eq (3). The result-
ing 2,000 upper and 2,000 lower cutoffs for each final drug-exposure model were averaged
to yield the final set of cutoffs. We call these cutoffs the DEMax cutoffs. If a DES for a drug is
less than both cutoffs for that drug, then we discretize that DES as unexposed (U). If a DES is
greater or equal than the lower cutoff, but less or equal than the upper cutoff, we discretize that
DES as intermediate exposure (IE). Finally, if a DES is greater than both cutoffs, then we discre-
tize that DES as exposed (E).
4.8.4. Phenotypically-guided cutoffs for prediction of phenotypic in-vitro drug resis-
tance (pheno cutoffs). A set of clinically relevant cutoffs for PhenoSense GPPs was obtained
from the HIVdb website [14] and is composed as follows. 3TC: 3 and 20; ABC: 3 and 6; AZT: 3
and 10; d4T: 1.5 and 2; ddI: 1.5 and 2; TDF 1.5 and 4; all non-nucleoside reverse-transcriptase
inhibitors (NNRTIs): 3 and 10; and all INIs 4 and 20. The set of clinically-relevant cutoffs were
used for discretizing PhenoSense GPPs in DPheno into the categories susceptible (S), intermedi-
ate (I) or resistant (R), henceforth called the true labels. The genotypes associated with these
GPPs were interpreted with the final DES models. For each drug, an upper and a lower DES
cutoff yield predicted GPP labels. These cutoffs, which we call pheno cutoffs, are determined
such that the sum of the penalties quantifying the differences between the true labels and the
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predicted labels is minimized. An individual penalty equals one, if the true label was R and the
predicted label was S. If the true label is I, and the predicted label S, the penalty equals 0.75. All
other differences between true and predicted labels were penalized with the value 0.5, while
the equality of true and predicted labels was not penalized. Pheno cutoffs allow for discretiza-
tion of a DES for a drug as susceptible (S), intermediate (I) or resistant (R). Further details on
the cutoff-determination procedure, including the rationale for choosing the penalty values
follow.
The error matrix E 2R3x3 Eq (4) was defined for penalizing the misclassification of a discre-
tized value δs with label l 2 {1,2,3} and predicted label ^l
^











The rationale for choosing the values of the error matrix follows. Diagonal entries are zero,
as correct classification incurs no penalty. From a clinical perspective, the worst kind of mis-
classification that can occur is the classification of a resistant viral strain (label 3) as susceptible
(label 1), since the prescription of a therapy including a thus misclassified compound could
compromise the susceptibility of all compounds in the therapy. Therefore, this kind of misclas-
sification was assigned the maximum penalty, one. Misclassification of a resistant strain as
intermediate (label 2) deserves a smaller penalty, as surpassing the lower cutoff indicates a
clinically-relevant decrease in susceptibility, albeit implying that some susceptibility is given.
Therefore, this kind of misclassification was assigned the penalty 0.75. All other types of mis-
classifications are considered equally undesirable, but less severe than the first two, and were
assigned the penalty 0.5. Clinically-relevant cutoffs were used to discretize PhenoSense GPPs
in DPheno with Function (2), yielding their labels. The genotypes s associated with these GPPs
were interpreted with the DES models. For each drug involved in a GPP, 2,000 bootstrap repli-
cates of the PhenoSense GPPs in DPheno were sampled. In order to assign to each of the three
classes the same weight in this procedure, each bootstrap replicate was constructed using an
equal number of GPPs with each label. For each drug, this number was equal to the maximum
number of GPPs with a certain label. Each bootstrap replicate was used to determine a lower
and an upper cutoff ĉL ,̂cU which minimizes the sum of the penalties Eðl;̂lÞ for each label l = dis-
cretize(cL, cU, RFs) with corresponding prediction l̂ ¼ discretizeð̂cL; ĉU ;DESsÞ for a resistance
factor RF and a drug-exposure score DES associated with genotype s. The resulting 2,000 cut-
off pairs for each drug and DES model were averaged, yielding the final phenotypically guided
cutoffs. If a DES for a drug is less than both cutoffs for that drug, then we discretize that DES
as susceptible (S). If a DES is greater or equal than the lower cutoff, but less or equal than the
upper cutoff, we discretize that DES as intermediate (I). Finally, if a DES is greater than both
cutoffs, then we discretize that DES as resistant (R).
4.8.5. Extraction of input-feature weights from drug-exposure models. For the purpose
of displaying the input features (i.e. HIV-1 substitutions, insertions, and deletions) with the
largest influence on a DES interpretation, we represented the SVCs that produce DES as linear
functions. Let xi 2 {0,1}p, i 2 {1, . . ., n} be the Support Vectors for a given DES model, αi 2 R
their corresponding Support-Vector coefficients, and ρ 2 R their intercept. The linear-func-




aixixs   r; ð5Þ
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where xs 2 {0,1}p is the encoding for input sequence s. Given an encoded sequence xs, the linear
Function (5) produces the same numerical output as the corresponding DES SVC. The linear
function consists of an offset (also called y-axis intercept) and p coefficients that correspond to
the components of the vectors that encode each sequence. The vector
Pn
i¼1 aixi contains these
coefficients (also called weights). Since the encoding of the sequence xs is binary, DES calcula-
tion can be performed by adding the offset to the coefficients that correspond to the input fea-
tures that are present in sequence s. In our web service, we display for each drug a selection
of features of the input sequence. These features have the largest absolute values of the coeffi-
cients in the linear-function representation of DES models. Features with positive coefficients
increase DES and are displayed in red. Features with negative coefficients decrease DES and
are displayed in green.
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51. Hertogs K, de Béthune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, et al. A rapid method for
simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in
recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral
drugs. Antimicrob. Agents Chemother. 1998; 42:269–76. PMID: 9527771
52. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A Novel Phenotypic Drug Sus-
ceptibility Assay for Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 2000;
44:920–8. PMID: 10722492
53. Pineda-Peña A-C, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, et al. Automated subtyp-
ing of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the
new REGA version 3 and seven other tools. Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect.
Dis. 2013;
54. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R
Foundation for Statistical Computing; 2014. http://www.R-project.org
55. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioin-
forma. Oxf. Engl. 2005; 21:3940–1.
56. Platt J. Probabilistic Outputs for Support Vector Machines and Comparisons to Regularized Likelihood
Methods. Adv. Large Margin Classif. MIT Press; p. 61–74.
Predicting HIV-1 exposure to antiretroviral drugs
PLOS ONE | https://doi.org/10.1371/journal.pone.0174992 April 10, 2017 27 / 27
